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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is an inter-
stitial lung disease characterized by the accumulation
of inflammatory cells in the air spaces, and fibrosis
of alveolar walls and the interstitium (1, 2). Despite
a worldwide effort, the pathogenesis of IPF is still
unclear. The prognosis in IPF is poor, and there is
currently no fundamental treatment for the disease
(1, 3). The clinical course of IPF is not uniform among
patients with the disease (3-5). Although in most
patients, the diseases are of slow progression on a
yearly basis, it is, in occasional patients, in a phase
of subacute progression on a weekly basis (3-5).
We have also observed that some patients whose
clinical course is chronically progressive suddenly
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show a rapid clinical deterioration (6). Such exacer-
bation often proves fatal.
Interleukin-1 (IL-1) exists in two genomic forms,
IL-1 α and IL-1 β, which share many biologic ac-
tivities (7-11). Although the precursor for IL-1 β re-
quires cleavage to reveal its IL-1α activity, the proIL-1α
is fully active as a precursor and remains intracellular
(7-9). IL-1 is recognized as the essential mediators
of inflammatory reactions (7-9), and is also suspect-
ed of being implicated in fibrogenic processes, since
it can increase both the growth of fibroblasts and
the collagen secretion rate (12, 13). Therefore, IL-1 is
thought to play an important role in the pathogenesis
of interstitial pneumonia and fibrosis (14-16). How-
ever, the regulated mechanism neutralizing IL-1 α
activity in vivo is known to exist in interstitial lung
diseases, including IPF. Indeed, it was reported
that IL-1ra, which neutralizes IL-1α activity, was in-
creased in interstitial lung diseases, and the IL-1/
IL-1ra ratio was thought to be important when in-
vestigating these diseases (14, 15, 17). However, it
is also thought important to investigate the mecha-
nism of IL-1α regulation in IPF patients, because
alveolar macrophages, which are key cells in the
pathogenesis of IPF, contained much IL-1 α which
has an active precursor form (8, 18).
Autoantibodies to several cytokines, including
IL-2 (19), TNF-α (20), IFN-γ (21), IL-6 (22), MCP-1
(23), IL-8 (24) and IL-10 (25) have recently been iden-
tified in normal human plasma. Autoantibodies to
IL-1α (IL-1α autoantibodies) were also found in sera
of patients with inflammatory process, such as rheu-
matoid arthritis and juvenile chronic arthritis, in
addition to asymptomatic subjects (26-34). It is
known that IL-1 α autoantibodies neutralize IL-1 α
activity specifically in vitro (29-31, 35), while IL-1ra
blocks the activity of both IL-1α and IL-1β (7-8).
IL-1 α autoantibodies in healthy subjects are known
to be mostly of the IgG ( IgG1 and IgG4) and these
antibodies have remarkably high binding affinities
to IL-1α (Kd=10-9-10-11M) (28, 31, 36, 37). Therefore,
it is conceivable that these antibodies play a regu-
latory role in vivo , controlling immunoinflammatory
reactions (38). Thus, it has been suggested that these
autoantibodies may be involved in modulating or
in the pathogenesis of certain diseases.
In this study, to clarify the role of IL-1α autoantibodies
in patients with rapidly progressive IPF, we investi-
gated the IL-1α autoantibodies in serum from these
patients, and also investigated the changes in titers
of the IL-1α autoantibodies in serum from progres-
sive IPF patients. Moreover, fresh frozen plasma
(FFP) obtained from normal healthy donors, which
contained rich IL-1 α autoantibodies, was adminis-
tered intravenously to progressive IPF patients, intra-
venously and its half life was calculated and com-
pared with that in control patients.
MATERIALS AND METHODS
Study Population
The subjects studied consisted of 17 patients with
rapidly progressive IPF. The patients were selected
on the basis of two criteria : (1) Rapidly progressive
IPF. Rapid progression was defined as an increased
dyspnea (an increase of more than 1 grade in the
Hugh-Jones classification system) or a decrease in
PaO2 (>10 mmHg in the same condition) during the
previous 1 month, and the presence of ground glass
attenuation in high resolution computed tomography
(HRCT). Since clinical deterioration may result from
infection, heart failure, cancer, our thromboembolism,
rather than disease progression (3), we excluded such
patients after clinical evaluation, including CT, sputum
examination and echo cardiography. (2) The likelihood
of treatment with weekly high-dose corticosteroids of at
least 3 cycles. A cycle of high dose corticosteroid pulse
therapy consisted of intravenous methylprednisolone
(1000 mg/day) for 3 consecutive days, followed by
oral prednisolone 60 mg/day for 4 days. After 3 cycles
of pulse therapy and/or immunosuppressive drugs
were administrated to most of the non-responders,
and a gradual tapering of the oral corticosteroid was
started for the responders.
Of the 17 patients, 12 were men and 5 werewomen.
The age range was 46 to 73 yr (mean±SD : 67.6±7.3)
(Table 1). Diagnosis of IPF was based on the histologi-
cal features in specimens obtained from postmorten
examination, open lung biopsy, video-associated
thoracoscopic biopsy, or clinical and radiological
features including honeycombing in HRCT with
histology-proven interstitial pneumonia, which did
not contradict the diagnosis of IPF, in specimens
obtained from transbronchial lung biopsy. Patients
who fulfilled the diagnostic criteria of collagen vas-
cular diseases were excluded. Fine crackles in both
lungs were noted in all patients. None of the patients
had been treated with oral corticosteroids or cytotoxic
agents in the past or at the time of deterioration. The
patients were classified as current smokers (S) if they
had smoked within 1 yr ; ex-smokers (EX) if they had
not smoked for 1 yr but had smoked previously ; and
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never-smokers (NS). The degree of dyspnea was de-
scribed according to the Hugh-Jones classification.
From arterial blood gas analysis at less than 24 h be-
fore treatment, the alveolar-arterial difference of oxy-
gen (A-aDo2) was calculated. It should be noted that
the percent vital capacity shown in Table 1 was ob-
tained up to 3 weeks before treatment, not specifi-
cally just prior to treatment.
The patients outcome were shown in Table 1. Seven
patients responded to the treatment as evidenced
by an increased PaO2 with the same condition (>10
mmHg) and decreased dyspnea (a decrease of more
than 1 grade in the Hugh-Jones classification). They
survived for at least 3 months after treatment. Ten
patients failed to respond to the treatment and died
from progressive respiratory failure within the 2
months.
In eleven cases (case 1 to 11), venous blood was
obtained on the first hospital day (before treatment),
when the patients were admitted to our hospital due
to severe symptoms, and on the 21st hospital day.
In six cases (case 12 to 17), venous blood was ob-
tained before treatment. Serum was obtained and
stored at -80℃. Serum LDH levels were determined
according to the method of Wroblewski La Due
(normal range : 220-450 IU/L).
The control group consisted of 6 patients (5 pa-
tients with chronic obstructive pulmonary disease
and 1 patient with lung cancer). The age range was
54 to 75 yr (68.0±8.5), and 5 were male and one was
female. The patients of the control group had no in-
flammatory findings.
Measurement of IL-1α autoantibodies
Human recombinant IL-1α (rIL-1α) was prepared
as described previously (39). IL-1α autoantibodies
in serum were measured using radioimmunoassay
(RIA) as described previously (31). Briefly, duplicate
samples of 50 ml of serum or standard dilutions of
monoclonal antibodies to IL-1 α, ranging from 5 to
640 ng/ml, were mixed with 125I-rIL-1 α. Each sam-
ple was mixed with 0.1% bovine serum albumin/
phosphate buffer saline (BSA/PBS) containing 5 mM
ethylenediaminotetraacetic acid (EDTA)/0.05% NaN3,
and each standard dilution of rhIL-1αwas mixed with
0.1% BSA/PBS containing 5 mM EDTA/0.05% NaN3
and carrier buffer (2% bovine gamma globulin). When
antigen-antibody binding had reached equilibrium
after overnight incubation at room temperature, each
sample was mixed with 25% polyethylene glycol (MW
6000) and incubated for 1h. Then, the tubes were
centrifuged at 3000 rpm for 15 min, and the radio-
activities of the precipitates were counted in an auto-
mated gamma-spectrometer. The sensitivity of this
assay for IL-1 α autoantibodies was 5 ng/ml.
Characterization of IL-1α autoantibodies in serum
from patients with rapidly progressive IPF
To characterized IL-1α autoantibodies that appeared
in serum of patients on the 21st hospital day, we used
Table 1. Background and outcome of patients
Patient No. Age/Sex Smoking＃
Dyspnea
(Hugh-Jones)
%VC AaDo2 LDH (IU/L) CRP (mg/dl) Outcome
1 K. O.
2 T. S.
3 M. N.
4 S. H.
5 I. H.
6 O. N.
7 Y. M.
8 Y. K.
9 O. M.
10 K. H.
11 T. K.
12 Y. M.
13 Y. H.
14 M. H.
15 O. T.
16 Y. T.
17 U. S.
65/M
71/M
70/M
61/M
73/F
70/M
70/M
46/M
70/M
57/F
70/M
70/M
70/M
77/M
73/F
72/F
65/F
S
S
EX
EX
NS
EX
S
EX
EX
NS
EX
S
S
S
NS
NS
NS
IV
I I I
I I I
I V
IV
I I I
IV
I I I
IV
IV
IV
IV
IV
IV
IV
IV
I I I
60
64
56
54
NA＊
58
68
67
NA
44
NA
58
NA
60
NA
NA
40
73.6
74.6
101.0
126.2
164.6
52.0
48.5
75.3
612.7
82.6
91.6
226.5
450.6
134.0
320.2
109.3
91.6
520
480
685
618
564
522
600
540
1856
872
549
600
520
650
823
492
630
３．２０
０．２６
４．２５
５．２８
１．５６
０．９２
４．１５
１．８２
２．７３
１５．７６
２．６０
４．１５
３．２０
３．５５
１．３０
３．５０
４．３０
Deceased
Surviving
Surviving
Deceased
Deceased
Surviving
Surviving
Deceased
Deceased
Deceased
Surviving
Surviving
Deceased
Deceased
Deceased
Deceased
Surviving
＊ NA ; not available
＃ smoking status as defined in Materials and Methods
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serum containing high IL-1α autoantibody levels ob-
tained from IPF, and investigated the immunoglobulin
class of the IL-1α autoantibodies. The serum was
applied to a protein A agarose column. After wash-
ing with binding buffer (50 mM sodium borate with
3M NaCl, pH9.0), the bound material was eluted
with elution buffer (100 mM glycine, pH 2.5) and
collected in 2 ml fractions. The IL-1α autoantibodies
level in each fraction was measured using RIA. The
serum IL-1 α autoantibodies were also fractionated
using gel filtration with a Superose 12 HR 10/30 col-
umn (Pharmacia, Uppsala Sweden). Serum was ap-
plied to a column preequilibrated with 50 mMTris-HCl
containing 0.5 M NaCl and 5 mM EDTA (pH 8.0)
and eluted with the same buffer. The elute was col-
lected in 0.5 ml fractions and the IL-1α autoantibody
concentration of each fraction were measured using
RIA.
Preparation of IL-1α autoantibodies rich plasma
Fresh frozen plasma (FFP) was obtained from
healthy blood donors at the Tokushima Blood Trans-
fusion Center (Tokushima, Japan). This plasma is
permitted to be used for blood transfusion. The level
of IL-1α autoantibodies in plasma was measured,
and the plasma with high titers of IL-1α autoantibodies,
i.e., a level over 640 ng/ml, was selected and stored
at -80℃ until the transfusion.
Half life of exogeneous IL-1α autoantibodies in
rapidly progressive IPF
We investigated serum IL-1 α autoantibody levels
after intravenous administration of FFP with high
levels of IL-1 α autoantibodies at the indicated time
intervals, and measured the half life (T1/2). We
studied 12 patients including 6 IPF patients (case
12-17) and 6 control patients. In the IPF patients, 5
units of FFP were administered after the first pulse
therapy. IL-1 α autoantibody levels of serum from
these patients were less than 5 ng/ml before IL-1 α
autoantibody rich plasma administration. Serum was
obtained on days 1, 3, 7 and 14 after intravenous ad-
ministration of FFP. This investigation was approved
by the Tokushima University ethics committee. In-
formed consent was obtained from each patient or
the patient’s family.
Statistical Analysis
Statistical analysis was performed using the
Mann-Whitney U test, and p values of 0.05 or less
were regarded as statistically significant.
RESULTS
IL-1 α autoantibodies in serum from patients with
rapidly progressive IPF
We measured IL-1α autoantibodies in serum from
patients with progressive IPF on the first hospital
day and the 21st hospital day. On the first hospital
day, IL-1α autoantibodies in serum were detected
in 5 of 11 patients with progressive IPF, with a level
between 10 and 168 ng/ml, while they were not
detected in the remaining 6 patients. On the 21st
hospital day, IL-1α autoantibodies were detected in
all IPF patients, its level was between 17 and 1273
ng/ml and was increased compared with that on the
first hospital day (Figure 1). The level of IL-1α
autoantibodies on the 21st hospital days was not sig-
nificantly different among the outcome of patients.
Characterization of IL-1α autoantibodies appeared
in serum of patients with progressive IPF
To characterize IL-1α autoantibodies that appeared
in serum of progressive IPF patients, we used serum
with high levels of IL-1α autoantibodies obtained
from 5 patients. The sample was applied to a protein
A agarose column. After washing with the binding
buffer, we obtained the IgG fraction using an elution
buffer. RIA showed that the high titer of IL-1α
autoantibodies was presented only in the IgG fraction
(Figure 2A). Furthermore, the serumwas fractionated
using gel filtration, and the molecular size of IL-1 α
autoantibodies corresponded to that of IgG (Figure
2B). All samples from the 5 patients which were
examined showed similar findings.
Half life of exogeneous IL-1α autoantibodies in
patients with rapidly progressive IPF and control
patients
IL-1α autoantibodies in rich FFP was adminis-
trated to 6 progressive IPF patients and 6 control
patients. All IPF patients were treated with high
dose steroid therapy and all control patients were
stable. Although IL-1α autoantibodies which might
be produced in the process of exacerbation, could
not be distinguished from IL-1 α autoantibodies in
FFP, the serum IL-1α autoantibody levels were mea-
sured after administration of IL-1 α autoantibodies
in rich plasma at the indicated interval, and the half
life (T1/2) of the exogenous IL-1 α autoantibodies
was calculated. As shown in Figure 3, T1/2 in pro-
gressive IPF patients was significantly shorter than
that in control patients (mean±SD;71.1±31.8hr v.s.
352±98.3 hr, p<0.001). Clinical change in these pa-
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Fig. 1. The change of IL-1 α autoantibody levels in
serum from rapidly progressive IPF patients. Serum
from IPF patients was obtained on the first hospital
day (A) and 21st hospital day (B), and the level of
IL-1α autoantiboides were measured using RIA with
a detection limit of 5 ng/ml as described in Materials
and Methods.
Fig. 2. Characterization of IL-1α
autoantibodies appeared in serum of
patients with rapidly progressive IPF.
(A) Fractionation of serum IL-1α
autoantibodies using a protein A agarose
column. Serum of patients were applied
to the protein A column. After washing
with binding buffer, protein was eluted
in 2 ml fractions using an elution buffer.
(B) Analysis of IL-1 α autoantibodies
via gel filtration. Serum of patients was
fractionated using gel filtration with a
Superose 12 HR 10/30 column. Molecu-
lar marker : A ; glutamate dehydrogenase
(290kD), B ; lactate dehydrogenase
(142 kD), C ; enolase (67 kD), D ; adenylate
kinase (32 kD),E ; cytochromeC(12.4 kD).
The titer of the IL-1 α autoantibodies
in each fraction was measured using
RIA as described inMaterials andMeth-
ods. The same findings were observed
in 5 different cases.
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tients could not be estimated after IL-1α autoantibody
administration.
DISCUSSION
The present study demonstrated that the level
of IL-1α autoantibodies in serum obtained from pa-
tients with rapidly progressive IPF was increased
during their clinical course, despite administration
of high dose steroids. Furthermore, IL-1α autoantibodies
which appeared in serum, were eluted at a molecular
size which corresponded to IgG. IL-1α autoantibodies
in rich FFP was administrated intravenously to pa-
tients with rapidly progressive IPF, and the T1/2
was calculated. The T1/2 obtained from IPF patients
was shorter than that from control patients.
IL-1α autoantibodies were shown to be capable
of specifically inhibiting the activity of IL-1α (30,
31, 33, 40). These antibodies bind to natural proIL-1α
as well as 17 kD recombinant IL-1α (41). In this re-
gard, IL-1α autoantibodies might be present to modu-
late immune inflammatory reaction by inhibition of
IL-1α activity, and this is also thought to play an im-
portant role in the pathogenesis of progressive IPF.
The level of IL-1 α autoantibodies was increased in
serum from patients with progressive IPF on the 21st
hospital day compared with that on the first hospital
day, despite treatment. The IL-1α autoantibodies
might be presented in response to lung tissue inju-
ry and their presence might reflect the degree of tis-
sue injury. The IL-1 α autoantibodies that appeared
in serum obtained from progressive IPF patients on
the 21st hospital day were eluted with an apparent
molecular weight of 100,000-200,000, which corre-
sponds to a subclass of the IgG fraction. Moreover,
a substantial amount of this material was bound to
protein A, which binds with high specificity to the
Fc regions of IgG1, IgG2 and IgG4. These observa-
tions suggest that IL-1 α autoantibodies were of IgG
class and our findings were similar to that of nor-
mal subjects (28, 31).
Next, we administrated intravenously IL-1α
autoantibodies in rich FFP to rapidly progressive
IPF patients, and estimated the half life of IL-1α
autoantibodies. Svenson et al. reported that pharma-
ceutical preparations of human IgG contain specif-
ic and neutralizing, high affinity antibodies against
IL-1α and IL-6, and the presence of these autoantibodies
may help explain why high dose IgG therapy is ben-
eficial in a number of pathogenetically obscure
immunoinflammatory disorders (42). Moreover, Ross
et al . demonstrated that in vivo antibodies against
IFN-α, IL-1α and IL-6 were increased after high
dose IgG therapy (43). Interestingly, the half life
of exogeneous IL-1 α autoantibodies in progressive
IPF patients was shorter than that in control patients.
However, the half life of exogenous IL-1α autoantibodies
might not be correct, because we could not distin-
guish between exogeneous and endogeneous IL-1α
autoantibodies, which appeared during disease pro-
gression. This is an important limitation of the present
study. Actually, the IL-1α autoantibody levels increased
faster after administration of IL-1 α autoantibodies
in rich FFP was decreased than that of control pa-
tients. Exogenous IL-1α autoantibodies are thought
to be consumed to neutralize IL-1α. In this regard,
the level of IL-1 α autoantibodies that appeared in
serum from patients might be decreased in the dis-
ease condition. These findings suggest that excess
extracellular IL-1α ctivity including mature and
proIL-1 α were present in progressive IPF patients
and it is likely that IL-1 α autoantibodies might be
present to regulate IL-1α activity. Although the
cells which produce IL-1α in progressive IPF were
unclear, monocytes/macrophages, endothelial cells,
dendritic cells and fibroblasts were shown to express
IL-1α (7). Isolated peripheral blood monocytes ex-
pressed more IL-1β than IL-1α (44-45). However,
alveolar macrophages released more cell associated
IL-1α than did blood monocytes (45). Recently, Janson
et al. reported that cell lysate in alveolar macrophages
Fig. 3 Half life of exogenous IL-1 α autoantibodies in patients
with progressive IPF and control patients. IL-1 α autoantibodies
rich FFP was administrated to 6 patients and 6 controls. The
concentration of IL-1 α autoantibodies in serum was measured
at the indicated time using RIA, as described in Materials and
Methods, and the half life was calculated. Significant difference
between the IPF group and the control group, p<0.01.
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stimulated with LPS contained high levels of IL-1α
(46). For this, alveolar macrophages were thought
to be a crucial source of IL-1α production in rapidly
progressive IPF. Since exogenous IL-1α autoantibodies
inhibit IL-1 α activity, the effect of these antibodies
on disease activity in progressive IPF patients might
be expected. However, we could not estimate the
clinical effects of these antibodies in the administrated
cases, because all of these patients were treated with
high dose steroid therapy, and IL-1α autoantibodies
in rich FFP might have contained autoantibodies to
other cytokines, such as IL-2, IL-6, IL-8, IL-10 and
IFN-γ, or other factors.
Although the physiological or pathophysiological
roles of autoantibodies to IL-1 α are still unknown,
IL-1α autoantibodies can be a natural inhibitor and
may play a highly significant role in regulation of
IL-1 α action in vivo . Additionally, it may play a sig-
nificant role in the kinetics of IL-1 α, although it is
still unknown whether the immune complexes are
scavenged more quickly than free IL-1 α or wheth-
er autoantibodies act as an IL-1α reservoir to prolong
its half life (37). The role of IL-1α autoantibodies
in vivo remains to be determined.
In conclusion, IL-1 α autoantibodies presented in
serum from progressive IPF might be generated in
response to the inflammatory processes of this dis-
ease and may act as a regulatory factor for IL-1α.
In this regard, recent isolation of a high affinity hu-
man monoclonal antibody to IL-1 α (47) might pro-
vide a new means for treatment of progressive IPF.
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